Vitamin d doses tested as COVID-19 shield in chicago study
NCT ID NCT04868903
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study looked at whether taking different amounts of vitamin D could lower the risk of getting COVID-19. About 1,475 adults from the Chicago area took either a low (400 IU), moderate (4,000 IU), or high (10,000 IU) daily dose of vitamin D for 9 months. Researchers tracked who got COVID-19 to see if higher doses offered more protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
1,475 people
The number who actually took part.
- Started
-
Nov 2020
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Subjects are able to participate if they: 1. Are 18 years or older. 2. Live or work in the Chicagloland area (Illinois counties: Cook, Lake, McHenry, DuPage, Kane, Kendall, Grundy, Will, and Kankakee; Indiana counties: Lake and Porter). 3. Are interested in vitamin D as a potential preventive measure against COVID-19 in which they self-administer a daily dose of vitamin D during the 9-month study period. 4. Are willing to attend the laboratory for drop-in appointments at UChicago Medicine or Rush University Medical Center every 3 months at 4 time points over a 9-month period for blood draws measuring COVID-19 antibodies, calcium, vitamin D and PTH levels. 5. Are willing to complete self-report measures at 4 time points over the course of 9 months by completing a 15-minute survey at intake by telephone or via web and 10-minute web-based follow-up surveys. Subjects are excluded from study participation if they: 1. Report ever having a positive COVID-19 PCR test result 2. Report being pregnant, planning to become pregnant, and/or report breastfeeding during the study period. 3. Report a history of chronic kidney disease, including a history of abnormal GFR and/or creatinine. 4. Report a history of hyperparathyroidism. 5. Report a history of increased falls. 6. Report a history of hypercalcemia. 7. Report a history of gastrointestinal absorptive disorders, including having undergone bariatric surgery. 8. Report a history of kidney stones (1 in past year or 2 in lifetime). 9. Report already taking more than 400 IU of vitamin D daily as recommended by their health care provider, excluding multivitamins and excluding supplements that include vitamin D and calcium together. 10. Report taking D2. 11. Report a history of sarcoidosis. 12. Screen positive for hypercalcemia during the initial blood test or follow-up blood tests. 13. Screen positive for primary hyperparathyroidism during the initial blood test. 14. Screen positive for COVID-19 antibodies during the initial blood test. 15. Have vitamin D levels of \>100ng/mL at study start, or \>250ng/mL during follow-up labs. 16. Are unwilling to provide blood samples during quarterly blood tests. 17. Are unwilling to take daily vitamin D.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-CoV-2 infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
University of Chicago
Chicago, Illinois, 60637-1622, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill stop COVID-19 before it starts?
- Why COVID-19 hits blood cancer patients harder: scientists map the immune clues
- The household maze: how does COVID-19 move between family members?
- New mRNA booster shot put to the test against comirnaty
- Can a second janssen shot cut severe COVID-19 in south africa?
- Can new vaccines outsmart COVID-19 variants?